Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors

Journal of Virology

Volumn 77, Issue 20, 2003, Pages 11082-11093

  Luker, Gary D ^a   Prior, Julie L ^a   Song, Jiling ^a   Pica, Christina M ^a   Leib, David A ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; FOOT DISEASE; FOOT PAD; GENE DELETION; HERPES SIMPLEX VIRUS 1; KNOCKOUT MOUSE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; VALIDATION PROCESS; VIRUS ISOLATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; CORNEA; HERPESVIRUS 1, HUMAN; LUCIFERASES; LUMINESCENT MEASUREMENTS; MEMBRANE PROTEINS; MICE; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; VIRUS REPLICATION;

EID: 0141788513     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.20.11082-11093.2003     Document Type: Article

References (45)

1. Butcher, E., and L. Picker. 1996. Lymphocyte homing and homeostasis. Science 272:60-66.
2. Cantin, E., D. Hinton, J. Chen, and H. Openshaw. 1995. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J. Virol. 69:4898-4905.
3. Cantin, E., B. Tanamachi, H. Openshaw, J. Mann, and K. Clarke. 1999. Gamma interferon (IFN-γ) receptor null-mutant mice are more susceptible to herpes simplex virus type I infection than IFN-γ ligand null-mutant mice. J. Virol. 73:5196-5200.
4. Casanova, J., and L. Abel. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20:581-620.
5. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajimi, A. Lanzavecchia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919-923.
6. Coles, R., S. Mueller, W. Heath, F. Carbone, and A. Brooks. 2002. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J. Immunol. 168:834-838.
7. Contag, C. H., and M. H. Bachmann. 2002. Advances in in vivo bioluminescence imaging of gene expression. Annu. Rev. Biomed. Eng. 4:235-260.
8. Cook, S., and D. Griffin. 2003. Luciferase imaging of a neurotropic viral infection in intact animals. J. Virol. 77:5333-5338.
9. Dufour, J., M. Dziejman, M. Liu, J. Leung, T. Lane, and A. Luster. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. Methods 168:3195-3204.
10. Dupuis, S., C. Dargemont, C. Fieschi, N. Thomassin, S. Rosenzweig, J. Harris, S. Holland, R. Schreiber, and J. Casanova. 2001. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293:300-303.
11. Dupuis, S., E. Jouanguy, S. Al-Hajjar, C. Fieschi, I. Al-Mohsen, S. Al-Jumaah, K. Yang, A. Chapgier, C. Eidenschenk, P. Eid, A. Ghonaium, H. Tufenkeji, H. Frayha, S. Al-Gazlan, H. Al-Rayes, R. Schreiber, I. Gresser, and J. Casanova. 2003. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33:388-391.
12. Espejo, C., M. Penkowa, I. Saez-Torres, J. Xaus, A. Celeda, X. Montalban, and E. Martinez-Caceres. 2001. Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice. Exp. Neurol. 172:460-468.
13. Farber, J. 1997. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61:246-257.
14. Farrar, M., and R. Schreiber. 1993. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11:571-611.
15. Fujii, S., K. Shimizu, M. Kronenberg, and R. Steinman. 2002. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3:867-874.
16. Furio, M., and C. Wordell. 1985. Treatment of infectious complications of acquired immunodeficiency syndrome. Clin. Pharm. 4:539-554.
17. Han, X., P. Lundberg, B. Tanamachi, H. Openshaw, J. Longmate, and E. Cantin. 2001. Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J. Virol. 75:3048-3052.
18. Katze, M., Y. He, and M. J. Gale. 2002. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2:675-687.
19. Kimberlin, D., C. Lin, R. Jacobs, D. Powell, L. Frenkel, W. Gruber, M. Rathore, J. Bradley, P. Diaz, M. Kumar, A. Arvin, K. Gutierrez, M. Shelton, L. Weiner, J. Sleasman, T. de Sierra, S. Soong, J. Kiell, F. Lakeman, and R. Whitley. 2001. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 108:223-229.
20. Leib, D. 2002. Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr. Top. Microbiol. Immunol. 269:171-185.
21. Leib, D., T. Harrison, K. Laslo, M. Machalak, N. Moorman, and H. Virgin. 1999. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J. Exp. Med. 189:663-672.
22. Loetscher, M., B. Gerber, P. Loetscher, S. Jones, L. Piali, I. Clark-Lewis, M. Baggiiolini, and B. Moser. 1996. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963-969.
23. Luker, G., J. Bardill, J. Prior, C. Pica, D. Piwnica-Worms, and D. Leib. 2002. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J. Virol. 76:12149-12161.
24. Mach, F., A. Sauty, A. Iarossi, G. Sukhova, K. Neote, P. Libby, and A. Luster. 1999. The interferon-γ inducible CXC chemokines IP-10, Mig, and I-TAC are differentially expressed by human atheroma-associated cells: implications for lymphocyte recruitment in atherogenesis. J. Clin. Investig. 104:1041-1050.
25. Mandl, S., C. Schimmelpfennig, M. Edinger, R. Negrin, and C. Contag. 2002. Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J. Cell. Biochem. Suppl. 39:239-248.
26. Muller, U., U. Steinhoff, L. Reis, S. Hemmi, J. Pavlovic, R. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921.
27. Norose, K., A. Yano, X. Zhang, E. Blankenborn, and E. Heber-Katz. 2002. Mapping of genes involved in murine herpes simplex virus keratitis: identification of genes and their modifiers. J. Virol. 76:3502-3510.
28. Ohteki, T., T. Fukao, K. Suzue, C. Maki, M. Ito, M. Nakamura, and S. Koyasu. 1999. Interleukin 12-dependent interferon gamma production by CD8alpha + lymphoid dendritic cells. J. Exp. Med. 189:1981-1986.
29. Perng, G., K. Mott, N. Osorio, A. Yukht, S. Salina, O. Nguyen, A. Nesburn, and S. Wechsler. 2002. Herpes simplex virus type 1 mutants containing the KOS strain ICP34.5 gene in place of the McKrae ICP34.5 gene have McKrae-like spontaneous reactivation but non-McKrae-like virulence. J. Gen. Virol. 83:2933-2942.
30. Pillay, D., M. Lipman, C. Lee, M. Johnson, P. Griffiths, and J. McLaughlin. 1993. A clinico-pathological audit of opportunistic viral infections in HIV-infected patients. AIDS 7:969-974.
31. Pollara, G., K. Speidel, L. Samady, M. Rajpopat, Y. McGrath, J. Ledermann, R. Coffin, D. Katz, and B. Chain. 2003. Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. J. Infect. Dis. 187:165-178.
32. Rader, K., C. Ackland-Berglund, J. Miller, J. Pepose, and D. Leib. 1993. In vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts. J. Gen. Virol. 74:1859-1869.
33. Sainz, B. J., and W. Halford. 2002. Alpha/beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J. Virol. 76:11541-11550.
34. - HSV vectors for dendritic cell-mediated immunotherapy. J. Virol. 77:3768-3776.
35. Samuel, C. 1998. Reoviruses and the interferon system. Curr. Top. Microbiol. Immunol. 233:125-145.
36. Smith, P., R. Wolcott, R. Chervenak, and S. Jennings. 1994. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma). Virology 202:76-88.
37. Stark, G., I. Kerr, B. Williams, R. Silverman, and R. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264.
38. Su, Y., J. Oakes, and R. Lausch. 1990. Ocular avirulence of a herpes simplex virus type I strain is associated with heightened sensitivity to alpha/beta interferon. J. Virol. 64:2187-2192.
39. Summers, B., and D. Leib. 2002. Herpes simplex virus type 1 origins of DNA replication play no role in the regulation of flanking promoters. J. Virol. 76:7020-7029.
40. Summers, B., T. Margolis, and D. Leib. 2001. Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread. J. Virol. 75:5069-5075.
41. Taniguchi, T., and A. Takaoka. 2001. A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell. Biol. 2:378-386.
42. Tsunobuchi, H., H. Nishimura, F. Goshima, T. Daikoku, Y. Nishiyama, and Y. Yoshikai. 2000. Memory-type CD8+ T cells protect IL-2 receptor alpha-deficient mice from systemic infection with herpes simplex virus type 2. J. Immunol. 165:4552-4560.
43. Tsunobuchi, H., H. Nishimura, F. Goshima, T. Daikoku, H. Suzuki, Y. Nishiyama, and Y. Yoshikai. 2000. A protective role of interleukin-15 in a mouse model for systemic infection with herpes simplex virus. Virology 275:57-66.
44. Vollstedt, S., M. Franchini, H. Hefti, B. Odermatt, M. O'Keefe, G. Alber, B. Glanzmann, M. Riesen, M. Ackermann, and M. Suter. 2003. Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J. Exp. Med. 197:575-584.
45. Wilson, T., and J. W. Hastings. 1998. Bioluminescence. Annu. Rev. Cell Dev. Biol. 14:197-230.